177Lu-EB-vipivotide tetraxetan

N/A

Report date: 2025/10/21 10:04:33
NME

Base Information

Drug Name177Lu-EB-vipivotide tetraxetan
Drug Alias Name177-Lu-EB-PSMA-617[177Lu]Lu-XT033
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionProstate-Specific Membrane Antigen inhibitorsPositron-emission tomography enhancersIonising radiation emitters
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPeking Union Medical College HospitalBeijing Xiantong International Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPeking Union Medical College HospitalBeijing Xiantong International Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Renal Cell
Inactive IndicationsCarcinoma, Adenoid Cystic

Other Information

ATC CodeN/A
Related LinksN/A